Why did Aradigm file for bankruptcy?
A year after a major knockback from the FDA for its lead inhaled antibiotic product and protracted efforts to try to resurrect the program, Aradigm has filed for bankruptcy.
Who are Aradigm's main backers?
The main backers for Aradigm have been Spanish drugmaker Grifols, which first bought into the inhaled ciprofloxacin program in 2013, and investment group First Eagle, which together own around 75% of its stock. It seems that they are reluctant to bankroll the company any further.
What makes a stock go up in price?
In the short term, things like quarterly earnings reports that beat expectations, analyst upgrades, and other positive business developments can lead investors to be willing to pay a higher price to acquire shares.
Why do Stocks go up without any news?
Sometimes demand for stocks in general increases, or demand for stocks in a particular stock market sector increases. A broad-based demand increase can drive individual stocks higher without any company-specific news. One example: The COVID-19 pandemic led to consumers increasing spending online at the expense of brick-and-mortar stores.
How were Aradigm's earnings last quarter?
Aradigm Co. (NASDAQ:ARDM) released its quarterly earnings results on Thursday, November, 15th. The company reported ($0.24) earnings per share for...
Who are Aradigm's key executives?
Aradigm's management team includes the following people: Dr. John M. Siebert , Exec. Chairman, Interim Principal Exec. Officer & Acting Principal...
Who are some of Aradigm's key competitors?
Some companies that are related to Aradigm include ReShape Lifesciences (RSLSD) , Aradigm (ARDMQ) , Magna-Lab (MAGAA) , Aksys (AKSY) , Echo Th...
What other stocks do shareholders of Aradigm own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aradigm investors own include Amarin (AMRN) , CRISPR Ther...
What is Aradigm's stock symbol?
Aradigm trades on the NASDAQ under the ticker symbol "ARDM."
How much money does Aradigm make?
Aradigm (NASDAQ:ARDM) has a market capitalization of $0.00 and generates $14.47 million in revenue each year. The company earns $-10.70 million in...
What is Aradigm's official website?
The official website for Aradigm is www.aradigm.com .
How can I contact Aradigm?
Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545 . The company can be reached via phone at 510-265-9000 or via email at [ema...
How were Aradigm's earnings last quarter?
Aradigm Co. (NASDAQ:ARDM) issued its earnings results on Thursday, November, 15th. The company reported ($0.24) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. The business had revenue of $0.28 million for the quarter. View Aradigm's earnings history.
Who are some of Aradigm's key competitors?
Some companies that are related to Aradigm include ReShape Lifesciences (RSLSD), Non-Invasive Monitoring Systems (NIMU), Escalon Medical (ESMC), Aradigm (ARDMQ), Trimedyne (TMED), Guided Therapeutics (GTHP), Magna-Lab (MAGAA), Nexeon MedSystems (NXNN), SpectraScience (SCIE), Aksys (AKSY), Echo Therapeutics (ECTE), Heart Tronics (HRTT), IMRIS (IMRSQ), Ivivi Technologies (IVVI) and NewCardio (NWCI). View all of ARDM's competitors..
What other stocks do shareholders of Aradigm own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aradigm investors own include Amarin (AMRN), CRISPR Therapeutics (CRSP), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), OpGen (OPGN) and (ALT).
How much money does Aradigm make?
Aradigm has a market capitalization of $0.00 and generates $14.47 million in revenue each year. The company earns $-10.70 million in net income (profit) each year or ($0.72) on an earnings per share basis.
How can I contact Aradigm?
Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected].
How much is Aradigm's deficit?
In its last quarterly results statement in November, Aradigm revealed that it had a total shareholders’ deficit of $23.5 million and working capital of just $700,000, and had accrued an accumulated deficit of just over $467 million.
Who is the backer of Aradigm?
The main backers for Aradigm have been Spanish drugmaker Grifols, which first bought into the inhaled ciprofloxacin program in 2013, and investment group First Eagle, which together own around 75% of its stock. It seems that they are reluctant to bankroll the company any further.
Is Aradigm bankrolling Apulmiq?
It seems that they are reluctant to bankroll the company any further. Aradigm’s long drive to get Apulmiq to market hit the buffers last January when the FDA said in a complete response letter that the company would have to run a new and expensive two-year trial before it could refile the drug.
Is Aradigm still under regulatory review?
Aradigm's inhaled ciprofloxacin drug is still under regulatory review in Europe. (kalhh/Pixabay) A year after a major knockback from the FDA for its lead inhaled antibiotic product and protracted efforts to try to resurrect the program, Aradigm has filed for bankruptcy.
Learn why the stock market and individual stocks tend to fluctuate and how you can use that information to become a better investor
Tim writes about technology and consumer goods stocks for The Motley Fool. He's a value investor at heart, doing his best to avoid hyped-up nonsense. Follow him on Twitter: Follow @TMFBargainBin
What affects stock price?
High demand for a stock drives the stock price higher, but what causes that high demand in the first place? It's all about how investors feel:
The big picture is what matters
Long-term investors, like those of us at The Motley Fool, don't much care about the short-term developments that push stock prices up and down each trading day. When you have years or even decades to let your money grow, analyst reports and earnings beats are often fleeting and irrelevant.